

PHARMACEUTICAL CARE AND ON CURBING PRESCRIPTION DRUG DIVERSION IN THE STATE, INCLUDING ANY RECOMMENDATIONS RELATED TO MODIFICATION OR CONTINUATION OF THE PROGRAM; AND

(4) PROVIDE ONGOING ADVICE AND CONSULTATION ON THE IMPLEMENTATION AND OPERATION OF THE PROGRAM, INCLUDING RECOMMENDATIONS REGARDING:

(I) CHANGES IN THE PROGRAM TO REFLECT ADVANCES IN TECHNOLOGY AND BEST PRACTICES IN THE FIELD OF ELECTRONIC HEALTH RECORDS AND ELECTRONIC PRESCRIPTION MONITORING; AND

~~(II) EMERGING DRUGS OF CONCERN THAT SHOULD BE IDENTIFIED AS MONITORED PRESCRIPTION DRUGS; AND~~

~~(III)~~ (II) THE DESIGN AND IMPLEMENTATION OF AN ONGOING EVALUATION COMPONENT OF THE PROGRAM.

21-2A-04.

(A) THE SECRETARY SHALL APPOINT A MULTIDISCIPLINARY CONSULTATION TEAM ~~WITHIN THE PROGRAM.~~

(B) THE MULTIDISCIPLINARY CONSULTATION TEAM SHALL REFLECT THE DIVERSITY AND BALANCE OF PERSPECTIVES REPRESENTED ON THE BOARD.

~~(B)~~ (C) THE MULTIDISCIPLINARY CONSULTATION TEAM SHALL CONSIST OF:

- (1) PROGRAM STAFF;
- (2) MEMBERS OF THE BOARD; AND

(3) ANY CONSULTANTS THAT THE SECRETARY DETERMINES WILL PROVIDE BROAD EXPERIENCE IN PAIN MANAGEMENT, SUBSTANCE ABUSE, AND PRESCRIPTION DRUG DIVERSION HELP ACHIEVE THE DIVERSITY AND BALANCE OF PERSPECTIVES REPRESENTED ON THE BOARD.

~~(C)~~ (D) IN ACCORDANCE WITH REGULATION, THE MULTIDISCIPLINARY CONSULTATION TEAM SHALL ASSIST A FEDERAL LAW ENFORCEMENT AGENCY, A STATE OR LOCAL LAW ENFORCEMENT AGENCY, OR A LICENSING ENTITY THAT HAS RECEIVED PRESCRIPTION MONITORING DATA FROM THE PROGRAM IN INTERPRETING THE DATA AND CONSIDERING WHETHER THE DATA, IN THE CONTEXT OF THE NATURE OF A PRESCRIBER'S OR A DISPENSER'S PRACTICE, A PATIENT'S MEDICAL CONDITION, OR ANY OTHER RELEVANT FACTS, SUGGEST THE NEED FOR FURTHER INVESTIGATION.

21-2A-05.

(A) FOR EACH MONITORED PRESCRIPTION DRUG THAT IS DISPENSED, A DISPENSER SHALL SUBMIT TO THE PROGRAM INFORMATION SPECIFIED BY THE SECRETARY, INCLUDING:

- (1) A PATIENT IDENTIFIER;
- (2) THE PRESCRIPTION DRUG DISPENSED;